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Abstract
The aetiological diagnosis of community-acquired pneumonia (CAP) is challenging in children, and serological markers would be useful
surrogates for epidemiological studies of pneumococcal CAP. We compared the use of anti-pneumolysin (Ply) antibody alone or with
four additional pneumococcal surface proteins (PSPs) (pneumococcal histidine triad D (PhtD), pneumococcal histidine triad E (PhtE),
LytB, and pneumococcal choline-binding protein A (PcpA)) as serological probes in children hospitalized with CAP. Recent pneumococ-
cal exposure (positive blood culture for Streptococcus pneumoniae, Ply+ blood PCR ﬁnding, and PSP seroresponse) was predeﬁned as
supporting the diagnosis of presumed pneumococcal CAP (P-CAP). Twenty-three of 75 (31%) children with CAP (mean age
33.7 months) had a Ply+ PCR ﬁnding and/or a ‡2-fold increase of antibodies. Adding seroresponses to four PSPs identiﬁed 12 additional
patients (35/75, 45%), increasing the sensitivity of the diagnosis of P-CAP from 0.44 (Ply alone) to 0.94. Convalescent anti-Ply and
anti-PhtD antibody titres were signiﬁcantly higher in P-CAP than in non P-CAP patients (446 vs. 169 ELISA Units (EU)/mL, p 0.031, and
189 vs. 66 EU/mL, p 0.044), conﬁrming recent exposure. Acute anti-PcpA titres were three-fold lower (71 vs. 286 EU/mL, p <0.001) in
P-CAP children. Regression analyses conﬁrmed a low level of acute PcpA antibodies as the only independent predictor (p 0.002) of
P-CAP. Novel PSPs facilitate the demonstration of recent pneumococcal exposure in CAP children. Low anti-PcpA antibody titres at
admission distinguished children with P-CAP from those with CAP with a non-pneumococcal origin.
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Introduction
Community-acquired pneumonia (CAP) is a common paedi-
atric infection and a leading cause of mortality worldwide in
young children [1,2]. Aetiological diagnosis is particularly
challenging [3]. Recent studies using modern microbiological
diagnostic tools have repeatedly identiﬁed Streptococcus
pneumoniae as a leading cause of CAP [4,5]. Recently, the
diagnosis of pneumococcal CAP (P-CAP) was enhanced with
new bacterial antibody and immune complex assays using
capsular C-polysaccharide or type-speciﬁc polysaccharides,
and pneumolysin (Ply) surface protein [6], a cytolytic toxin
involved in pneumococcal pathogenesis [7]. Serodiagnosis of
P-CAP remains particularly challenging in young children,
who are frequently colonized by S. pneumoniae and in whom
recent carriage acquisition may trigger serological responses
[8–10]. Diagnosis of P-CAP in paediatric studies relies upon
a combination of criteria showing recent S. pneumoniae expo-
sure with positive blood culture or PCR ﬁndings, and anti-
pneumococcal seroresponses [4–6]. Without a reference
standard, these assays remain incompletely validated and use-
less for individual diagnosis. However, they currently consti-
tute the best approach available to estimate pneumococcal
disease burden in studies.
Recently, probing of the antibody repertoire for pneumo-
coccal surface proteins (PSPs) identiﬁed approximately 140
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antigens [11]. Their contribution to diagnosis, recovery or
protection against subsequent infection remains unknown.
We investigated how additional PSPs would impact on the
serodiagnosis of P-CAP as compared with the use of anti-Ply
antibodies alone. Four PSPs were selected, primarily on the
basis of their availability, conservation across pneumococcal
strains (>97.5%) [12] (sanoﬁ Pasteur, unpublished data) and
putative role(s) in bacterial pathogenesis [13]. Pneumococcal
histidine triad D (PhtD) and pneumococcal histidine triad E
(PhtE) are thought to be involved in laminin binding and/or
zinc acquisition [14]. LytB is a choline-binding protein linked
to daughter cell separation [15], and possibly contributes to
bacterial spread. Pneumococcal choline-binding protein A
(PcpA) may play a role in bacterial adherence to respiratory
epithelium in the lower respiratory tract [16].
Here, we investigated antibody responses to four new
PSPs in children, their dynamics during CAP, and how these
anti-PSP responses differ between children with presumed
P-CAP and those with non-pneumococcal CAP (NP-CAP).
Materials and Methods
After written consent had been obtained, 99 children aged
£6 years were enrolled between 2003 and 2005 in a pro-
spective descriptive study on CAP in the University Hospitals
of Lausanne and Geneva (Switzerland) [17]. Children were
eligible if they presented with clinical signs of pneumonia
according to the WHO classiﬁcation [18]; children with
actively treated asthma, chronic underlying disease, immuno-
suppression or wheezing were excluded. Pneumonia was
deﬁned as: (i) non-severe when the child had only fever and
tachypnoea; (ii) severe when the child had, in addition,
increased work in breathing; and (iii) very severe when the
child had difﬁculty in feeding. One child had a positive blood
culture for S. pneumoniae. No child had received pneumococ-
cal vaccination. This study was approved by both Ethical
Committees.
Chest radiographs were reviewed by a senior radiologist
blinded to clinical and laboratory ﬁndings. The presence of
consolidation or pleural effusion with parenchymal inﬁltrate
deﬁned radiological pneumonia. Blood and nasopharyngeal
samples were assessed for viruses and bacteria. PCR analyses
on nasopharyngeal samples included 13 common respiratory
viruses, Mycoplasma pneumoniae, and Chlamydia pneumoniae,
and acute blood samples were assessed by Ply-speciﬁc PCR
[17]. Convalescent serology ﬁndings were obtained from 75/
99 children, who agreed to return 3 weeks later. Children
with paired samples were enrolled in the study. Samples
from 58 healthy children, matched by age, and admitted for
elective surgical procedures without evidence of acute infec-
tion, were used as controls.
Recombinant PhtD, PhtE, PcpA and LytB were expressed
in Escherichia coli as soluble proteins, and puriﬁed with com-
binations of ion-exchange chromatography. PhtD and PhtE
were full-length proteins, whereas PcpA and LytB were trun-
cated forms without the choline-binding domain. All four
were cloned from strain 14453 (serotype 6B). Each protein
was obtained at ‡90% purity. Serum samples were stored at
)20C until analysis. Paired acute–convalescent samples
were tested in the same run by indirect ELISA, with the use
of puriﬁed proteins to coat Immulon (Thermo Labsystem
Helsinki, Finland) plates, anti-IgG antibody (Cappel, Laboratory
Cochran Ville; PA), and 2,2¢-azino-bis(3-ethylbenzthiazoline-
6-sulphonic acid) substrate. Eight serial dilutions (two-fold) of
samples were performed to allow precise quantiﬁcation of
antibody titres. A common reference human AB serum was
used in each assay. Its antibody concentration in ELISA Units
(EU) was deﬁned by the reciprocal of its dilution at an opti-
cal density of 1.0. Results were expressed in EU/mL by
comparing individual optical densities to that of a reference
serum. A cut-off of 5 EU/mL was experimentally identiﬁed as
allowing reliable detection of serum concentrations. Concen-
trations below 5 EU/mL were given a titre of 2.5 EU/mL.
Antibody concentrations were log transformed to allow
comparisons of geometric mean concentrations (GMCs). A
signiﬁcant response in antibody titres was conservatively
predeﬁned as a ‡2-fold increase between acute-phase and
convalescent-phase samples. Children admitted for CAP with
a positive blood culture for S. pneumoniae, Ply+ PCR and/or
signiﬁcant anti-PSP responses to any PSP were considered to
have P-CAP, and were compared with those lacking such evi-
dence (NP-CAP). Additional analyses used a more stringent
criterion of a ‡4-fold increase to deﬁne seroresponses. Naso-
pharyngeal carriage was not used to deﬁne the origin of CAP.
Variables were compared with Student’s t-test, chi-square
tests, or Fisher’s exact test when appropriate. Serological
responses among groups were compared by using analysis of
variance. Logistic regression analysis was used to calculate
adjusted ORs and 95% CIs, controlling for any statistically
signiﬁcant demographic variable that might function as a con-
founder. Differences were considered signiﬁcant at p <0.05,
or when the 95% CI did not include 1.0. SPSS version 15.0
was used for analyses.
Results
Among 75 children (mean age 33.7 months) hospitalized with
CAP, 15 (20%) were Ply+ by PCR (Table 1). Rising anti-Ply
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IgG responses identiﬁed 16 (21%, ‡2-fold) or eight (11%, ‡4-
fold) children with P-CAP (Table 2). Consideration of Ply+
PCR and/or anti-Ply seroresponses as markers of P-CAP
increased this proportion to 31% (23/75, ‡2-fold) or 24%
(18/75, ‡4-fold) [17]. S. pneumoniae nasopharyngeal carriage
was detected in 24 (32%).
We ﬁrst compared the proportions of CAP children with
acute seroresponses to each of four additional PSPs.
Responses to LytB were rare (ﬁve, 7%). In contrast,
responses to PhtD, PhtE or PcpA were observed in 20%
(‡4 fold) to 32% (‡2 fold) of children (Table 2). A rising
response to one or more PSPs was observed in 44% (‡2-
fold) and 31% (‡4-fold), respectively. Such responses were
frequently directed against several PSPs (‡2 PSPs, 30%; ‡3
PSPs, 25%; ‡4 PSPs, 14%; ‡5 PSPs, 1%), providing strong evi-
dence of recent pneumococcal exposure. These fold changes
were marked for anti-PhtD (mean: 4.22), anti-PhtE (mean:
6.88), and anti-PcpA (mean: 5.62). Use of ‡2-fold or ‡4-fold
deﬁnitions for seroresponses had little impact on the
patient’s attribution to a P-CAP vs. an NP-CAP group (not
shown). Age did not inﬂuence fold changes of anti-PSP IgG
(R2 < 0.162 for all).
We then compared the contribution of anti-Ply alone vs.
anti-PSP for the diagnosis of P-CAP children with Ply+ PCR
ﬁndings in blood. Among 15 Ply+ PCR patients, eight (53%)
had ‡2 fold anti-Ply responses, yielding a negative predictive
value (NPV) of 0.88 and a positive predictive value (PPV) of
0.50. Single anti-PSP responses resulted in higher NPVs,
except for LytB, without improving PPVs (Table 2). Most
Ply+ PCR children (13, 87%) responded (‡2 fold) to one or
more of the PSPs tested (Table 1). Two non-responders
were a 2.5-month-old boy, presumably too young to rapidly
raise infection-driven B-cell responses, and a 43-month-old
girl admitted with >1-week history of cough and fever, who
already had high serum titres against the ﬁve tested PSPs
when admitted with lobar pneumonia. Thus, adding PhtD,
PhtE and PcpA to anti-Ply antibody markedly increased the
NPV (0.96) of serodiagnosis in P-CAP children.
Relying on acute/convalescent seroresponses provides the
demonstration of recent pneumococcal exposure. However,
such seroresponses may be elicited prior to admission.
Therefore, many clinical studies add a criterion of ‘high titres
at admission’, derived from comparisons with control chil-
dren, in their diagnostic algorithm [19,20]. Comparison of
the GMCs of the 38 CAP children older than 24 months
(mean age 43.1 months) at enrolment with those of 58
healthy control children (mean age 43.6 months) indicated
that anti-PSP IgG titres at admission were higher in control
children than in CAP children (in EU/mL: Ply, 370 vs. 200;
PthD, 185 vs. 93; PhtE, 345 vs. 215; PcpA, 500 vs. 170). This
remained true when only the 15 children with evidence of P-
CAP were included (not shown). Thus, reliance on ‘high’
anti-Ply titres at admission for the diagnosis of P-CAP was
not considered to be optimal in this study.
Our P-CAP deﬁnition identiﬁed 35 children with evidence
of acute pneumococcal exposure, of whom 15 (42%) had
Ply+ PCR ﬁndings, and deﬁned 40 NP-CAP children. Radio-
logical consolidation was present in 31/35 P-CAP (89%) vs.
19/40 (48%) NP-CAP patients (p <0.001). As expected from
the natural history of pneumococcal exposure and disease,
S. pneumoniae carriage was more frequent in P-CAP (46%)
than in NP-CAP children (20%, p 0.017). A viral agent was
identiﬁed in the respiratory secretions of 21/35 (60%) P-CAP
vs. 29/40 (73%, p not signiﬁcant) NP-CAP children. Univari-
ate analyses indicated that neither age, gender, clinical sever-
ity of pneumonia, duration of cough or fever nor antibiotic
TABLE 1. Seroresponses to pneumococcal surface protein
(PSP) in children with community-acquired pneumonia
(CAP) according to their pneumolysin (Ply) PCR status
Anti-Ply
seroresponse
‡2 fold
N (%)
Any PSP
seroresponse
‡2 fold
N (%)
Any PSP
seroresponse
‡4 fold
N (%)
Ply+ PCR (N = 15) 8 (53) 13 (87) 11 (73)
Ply– PCR (N = 60) 8 (13) 20 (33) 13 (22)
TABLE 2. Seroresponses to and
diagnostic performance of a panel
of surface pneumococcal proteins
in 75 children with community-
acquired pneumonia
Seroresponders
N (%)
GMC (EU/mL,
95% CI)
Comparison with children with Ply+ PCR
ﬁndings in the blood
‡2-fold ‡4-fold Sensitivity Speciﬁcity NPV PPV
Ply 16 (21) 8 (11) 154 0.53 0.87 0.88 0.50
PhtD 20 (27) 15 (20) 108 0.67 0.84 0.91 0.50
PhtE 24 (32) 14 (19) 239 0.80 0.79 0.95 0.46
PcpA 23 (31) 14 (15) 279 0.60 0.78 0.90 0.38
LytB 5 (7) 3 (4) 24 0.13 0.95 0.80 0.40
Any 33 (44) 23 (31) NA 0.87 0.72 0.96 0.39
EU, ELISA Units; GMC, geometric mean concentration; NA not applicable; NPV, negative predictive value; PcpA, pneu-
mococcal choline-binding protein A; PhtD, pneumococcal histidine triad D; PhtE, pneumococcal histidine triad E; Ply,
pneumolysin; PPV, positive predictive value.
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use within 30 days of admission differed between children
hospitalized for P-CAP and those hospitalized for NP-CAP.
This conﬁrms that clinical patterns alone may not reliably
identify children with P-CAP.
Assessment of the capacity of anti-PSP responses to iden-
tify P-CAP children indicated that anti-Ply IgG responses
would have missed 19/35 (47%) patients. Combining two
PSPs signiﬁcantly increased assay sensitivity (Table 3). The
combination of anti-Ply, anti-PcpA and anti-PhtE responses
yielded the optimal result of 0.97 for sensitivity and 0.98 for
NPVs. Unexpectedly, the maximal sensitivity of any combina-
tion of PSPs without PcpA remained below 0.70, suggesting
its importance in the serological diagnosis of P-CAP.
As pre-existing anti-pneumococcal antibodies may contrib-
ute to protection against pneumococcal disease, PSP-speciﬁc
immunity at admission was assessed in P-CAP and NP-CAP
children. Most patients had detectable acute antibodies to
several PSPs (‡2 PSPs, 96%; ‡3 PSPs, 92%; ‡4 PSPs, 89%; ‡5
PSPs, 86%), indicating past exposure/carriage. Correlations
between age and GMCs were strong for Ply (R2 = 0.63434),
PhtD (R2 = 0.63297), and PhtE (R2 = 0.59359), and weaker,
although signiﬁcant, for LytB (R2 = 0.45824) and PcpA
(R2 = 0.31625). Exposure-driven anti-PSP antibodies in chil-
dren indicated that anti-PcpA antibodies were present at high
titres in some children younger than 18 months (Fig. 1), their
increase with age being signiﬁcant (p 0.022) but less marked
than for other PSPs (p <0.001).
At admission, antibodies to Ply, PhtD, PhtE and LytB were
similar in P-CAP and NP-CAP children (Table 4 and Fig. 2),
suggesting comparable past exposure to S. pneumoniae and
B-cell response capacity. In striking contrast, anti-PcpA
GMCs were four-fold lower (71 vs. 286 EU/mL, p <0.001) in
P-CAP children, reﬂecting a greater proportion of NP-CAP
children with anti-PcpA titres at any value >10 EU/mL
(Fig. 2). At convalescence, anti-PcpA titres were similar in
both groups, whereas anti-Ply and anti-PhtD titres were
signiﬁcantly (Table 4) higher in P-CAP patients (Ply, 246 vs.
103 EU/mL; PhtD, 189 vs. 66 EU/L). Multivariate analyses
adjusting for gender, age and clinical scores conﬁrmed low
anti-PcpA titres (p 0.002) at admission as the only signiﬁcant
predictors of P-CAP vs. NP-CAP in our patients.
Discussion
The identiﬁcation of new PSPs has led to renewed interest
in the serological diagnosis of respiratory infections [6]. The
early recognition that S. pneumoniae is the causative agent of
CAP could have an important impact on targeted antimicro-
bial therapy. Furthermore, use of a PSP combination may
markedly improve the sensitivity of diagnosis of P-CAP in
epidemiological studies.
TABLE 3. Sensitivities of the combination of two anti-
pneumococcal surface protein (PSP) seroresponses for the
diagnosis of pneumococcal community-acquired pneumonia
(P-CAP)
Ply PhtD PhtE PcpA LytB
Ply 0.46 0.60 0.69 0.89 0.49
PhtD 0.60 0.57 0.69 0.91 0.63
PhtE 0.69 0.69 0.66 0.94 0.69
PcpA 0.89 0.91 0.94 0.66 0.72
LytB 0.49 0.63 0.67 0.69 0.14
PcpA, pneumococcal choline-binding protein A; PhtD, pneumococcal histidine
triad D; PhtE, pneumococcal histidine triad E; Ply, pneumolysin.
Sensitivities are calculated from the number of P-CAP patients with ‡2-fold
responses to one or two PSPs among all P-CAP patients.
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FIG. 1. Anti-pneumococcal surface protein serum IgG antibodies at
admission in children with community-acquired pneumonia (CAP).
PcpA, pneumococcal choline-binding protein A; PhtD, pneumococcal
histidine triad D; PhtE, pneumococcal histidine triad E; Ply, pneumolysin.
TABLE 4. Comparison of anti-pneumococcal surface protein
(PSP) seroresponses in children with non-pneumococcal
community-acquired pneumonia (NP-CAP) vs. those with
pneumococcal community-acquired pneumonia (P-CAP)
Stage
NP-CAP
(n = 40)
(EU/mL,
95% CI)
P-CAP
(n = 35)
(EU/mL,
95% CI) p-Valuea
Ply GMC Acute 104 119 0.777
Ply GMC Convalescent 103 246 0.033
PhtD GMC Acute 65 54 0.146
PhtD GMC Convalescent 66 189 0.044
PhtE GMC Acute 144 115 0.187
PhtE GMC Convalescent 141 448 0.06
PcpA GMC Acute 286 71 <0.001
PcpA GMC Convalescent 283 279 0.178
LytB GMC Acute 25 19 0.052
LytB GMC Convalescent 23 25 0.419
GMC, geometric mean concentration; PcpA, pneumococcal choline-binding pro-
tein A; PhtD, pneumococcal histidine triad D; PhtE, pneumococcal histidine
triad E; Ply, pneumolysin.
aP-CAP vs. NP-CAP.
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A sharp rise in serum antibodies within a few weeks is a
validated marker of recent microbial exposure in healthy
individuals. These antibody assays perform well in bacterae-
mic children [8]; however, they are less satisfactory for non-
bacteraemic P-CAP, which is frequent in children. A pneu-
mococcal surface adhesin A-based ELISA reached a speciﬁcity
of 0.98 and a sensitivity of 0.70 in adult Kenyans with pneu-
monia [9], whereas its sensitivity declined to 0.42 in children
[10]. Other studies have reported similarly low sensitivities
[21]. These poor performances were ascribed to a higher
prevalence of colonization in children. In general, nasopha-
ryngeal S. pneumoniae carriage has little effect on antibody
levels, and acute seroresponses are seen in <3% of healthy
young children [20]. In contrast, recent carriage acquisition
or otitis media may elicit antibody responses [8,22–24] and
reduce the speciﬁcity of serological diagnosis of CAP in chil-
dren. Notably, the speciﬁcity of PSP-based assays remains
much better than their sensitivity in children with CAP [10].
This suggests that colonization essentially confounds the
serological diagnosis of CAP through higher baseline anti-
body levels, limiting the ability to detect signiﬁcant antibody
rises, and thus assay sensitivity.
Here, we postulated that the sensitivity of PSP-based
serological assays could be improved by using several immu-
nogenic proteins and/or a combination of them. This was
largely conﬁrmed: past exposure did not elicit antibodies to
all PSPs, enabling seroresponses to other antigens. Conse-
quently, a combination of anti-PcpA, anti-PhtE and anti-Ply
responses identiﬁed children with evidence of recent pneu-
mococcal exposure, and increased assay sensitivity. In addi-
tion, PcpA was unexpectedly identiﬁed as a key diagnostic
marker of P-CAP: in its absence, assay sensitivity reached
a maximal value of 0.67, as compared with 0.92 for a
PcpA-containing PSP combination. The combined use of ﬁve
immunoprobes identiﬁed 34/75 (45%) CAP children with
evidence of acute pneumococcal responses, a proportion in
accordance with the presumed contribution of S. pneumoniae
to the aetiology of CAP in hospitalized children [5].
Severity scores were similar in our P-CAP and NP-CAP
children, despite more frequent lung consolidation in P-CAP
children. One could hypothesize that some NP-CAP children
had severe acute viral disease with diffuse lung disease that
did not present evidence of pneumococcal exposure. Fur-
thermore, we acknowledge the fact that our serology-based
diagnosis is not 100% sensitive and/or speciﬁc, and that this
could explain some misclassiﬁcation. However, in the
absence of a reference standard, we conservatively relied
upon the most frequently used deﬁnition to show recent
pneumococcal exposure and to identify patients with P-CAP.
Concerning PCR, Nakayama et al. [25] found, in a similar
clinical setting, that a comparable PCR method had high
sensitivity and speciﬁcity (respectively, 95% and 98%). Our
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deﬁnition may underestimate the proportion of children with
P-CAP, particularly in young infants, who may fail to raise
acute seroresponses. Our low rate of positive blood cultures
for S. pneumoniae in children with CAP is nevertheless higher
than that reported by others [4,21,26]. However, we cannot
exclude the possibility that some anti-PSP responses resulted
from recent carriage acquisition in children with NP-CAP.
Indeed, S. pneumoniae was more frequently identiﬁed in the
nasopharynx of P-CAP than of NP-CAP patients, in accor-
dance with other results [27] and the physiopathology of P-
CAP. However, anti-PSP responses were very strong and
were obtained against several PSPs, and most included anti-
PcpA antibodies that are not readily elicited through carriage
alone. Altogether, this supports the use of several PSPs
rather than a single PSP for the serodiagnosis of P-CAP.
Titres of antibodies to Ply, PhtD, PhtE and LytB at admis-
sion were similar in both groups, conﬁrming that these
patients were otherwise healthy children previously exposed
to S. pneumoniae. In striking contrast, anti-PcpA antibody
titres were three-fold lower in children admitted for P-CAP.
PcpA was ﬁrst characterized in 1998 as a protein with a
putative adhesion role [28]. PcpA mutant strains efﬁciently
colonize the murine nasopharynx but fail to adhere to the
lungs [29]. PcpA expression is downregulated by a metal-
dependent regulator and thus by high concentrations of
Mn2+ [29]. This provides a biological explanation for the
unique role of PcpA identiﬁed here in human pneumonia. Sal-
iva has the highest in vivo concentration of Mn2+ (36 lM).
Therefore, PcpA expression is repressed unless pneumococci
invade the lung or bloodstream, where the levels of Mn2+
are 1000-fold lower (20 nM) [30,31]. Consequently, anti-
PcpA responses result from pneumococcal disease rather
than colonization. Low anti-PcpA antibody titres at admission
suggest a primary episode of pneumococcal disease.
Whether PcpA antibodies are merely markers of protective
immunity induced by prior pneumococcal disease or play a
protective role against recurrence is not yet known. In sum-
mary, PcpA appears to play a critical role in pneumococcal
pneumonia, which should be validated in a larger study; such
a role would warrant its assessment as a diagnostic tool in
various settings, and as a potential vaccine antigen.
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